Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.

McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, Bennett NM, Scahill M, Niccolai LM, Brackney M, Griffin MR, Pemmaraju M, Querec TD, Cleveland AA, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):337-343. doi: 10.15585/mmwr.mm6815a1.

2.

Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M.

BMJ. 2019 Apr 3;365:l1161. doi: 10.1136/bmj.l1161.

3.

Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.

Moscicki AB, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, Spiryda LB, Gold MA.

J Low Genit Tract Dis. 2019 Apr;23(2):87-101. doi: 10.1097/LGT.0000000000000468.

PMID:
30907775
4.

The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.

Hall MT, Smith MA, Lew JB, O'Hallahan J, Fentiman G, Neal H, Sage M, Canfell K.

Gynecol Oncol. 2019 Mar;152(3):472-479. doi: 10.1016/j.ygyno.2018.10.045.

PMID:
30876491
5.

Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

Velentzis LS, Smith MA, Simms KT, Lew JB, Hall M, Hughes S, Yuill S, Killen J, Keane A, Butler K, Darlington-Brown J, Hui H, Brotherton JML, Skinner R, Brand A, Roeske L, Heley S, Carter J, Bateson D, Frazer I, Garland SM, Guy R, Hammond I, Grogan P, Arbyn M, Castle PE, Saville M, Armstrong BK, Canfell K.

Gynecol Oncol. 2019 Mar;152(3):465-471. doi: 10.1016/j.ygyno.2018.12.019.

PMID:
30876490
6.

Evaluation of Folate Receptor-Mediated Cervical Dyeing as a Method for Detection of Cervical Lesions.

Zhao Y, Li M, Li Y, Lv Q, Chen F, Li B, Zhang Z, Guo H, Lu D, Wang F, Zhai J, Feng L, Lai A, Li H, Yao C, Wei L.

J Low Genit Tract Dis. 2019 Apr;23(2):133-137. doi: 10.1097/LGT.0000000000000411.

PMID:
30817686
7.

Affective and Cognitive Attitudes on Cervical Health Behaviors Among Asian American Women.

Lee J, Carvallo M, Lee E, Chung J, Shin C.

Fam Community Health. 2019 Apr/Jun;42(2):123-132. doi: 10.1097/FCH.0000000000000216.

PMID:
30768477
8.

Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.

Ramezani A, Aghakhani A, Soleymani S, Bavand A, Bolhassani A.

BMC Infect Dis. 2019 Feb 12;19(1):142. doi: 10.1186/s12879-019-3780-2.

9.

Reimbursement Incentives to Improve Adherence to Follow-Up of Cervical Cancer Cytology Screening Results in Peru.

Ferris DG, Chen J, Isaac A, Braithwaite E, Beideck E, Mikail N, Krotish D, Waller JL.

J Low Genit Tract Dis. 2019 Apr;23(2):116-123. doi: 10.1097/LGT.0000000000000459.

PMID:
30741754
10.

Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group.

de Foucher T, Bendifallah S, Ouldamer L, Bricou A, Lavoue V, Varinot J, Canlorbe G, Carcopino X, Raimond E, Monnier L, Graesslin O, Touboul C, Collinet P, Neveu ME, Huchon C, Daraï E, Ballester M; Groupe de Recherche Francogyn, France.

Eur J Surg Oncol. 2019 Apr;45(4):659-665. doi: 10.1016/j.ejso.2018.11.014. Epub 2018 Dec 30.

PMID:
30685326
11.
12.

Knowledge and misconceptions of Saudi women about sexually transmitted infections.

Balbeesi A, Mohizea S.

J Egypt Public Health Assoc. 2017 Dec 1;92(4):235-239. doi: 10.21608/EPX.2018.22045.

13.

Analytical performance evaluation of the HPV OncoCheck assay for detection of high-risk HPV infection in liquid-based cervical samples.

Wang HY, Kim H, Park S, Park KH, Lee H.

Exp Mol Pathol. 2019 Feb;106:149-156. doi: 10.1016/j.yexmp.2018.12.008. Epub 2018 Dec 31.

PMID:
30605636
14.

Compliance to radiotherapy: A tertiary care center experience.

Gupta S, Rastogi K, Bhatnagar AR, Singh D, Gupta K, Choudhary AS.

Indian J Cancer. 2018 Apr-Jun;55(2):166-169. doi: 10.4103/ijc.IJC_517_17.

15.
16.

Hospice utilization in advanced cervical malignancies: An analysis of the National Inpatient Sample.

Sheu J, Palileo A, Chen MY, Hoepner L, Abulafia O, Kanis MJ, Lee YC.

Gynecol Oncol. 2019 Mar;152(3):594-598. doi: 10.1016/j.ygyno.2018.12.016. Epub 2018 Dec 23.

PMID:
30587442
17.

Factors Influencing Knowledge and Practice Regarding Cervical Cancer and Pap smear Testing among Omani Women

Alwahaibi N, Alsalami W, Alramadhani N, Alzaabi A.

Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3367-3374.

18.

Distribution of cervical abnormalities detected by visual inspection with acetic acid in Swaziland, 2011-2014: A retrospective study.

Ginindza TG, Almonte M, Dlamini X, Sartorius B.

Afr J Prim Health Care Fam Med. 2018 Oct 18;10(1):e1-e7. doi: 10.4102/phcfm.v10i1.1773.

19.

Knowledge and attitudes toward HPV infection and vaccination among immigrants and refugees in Italy.

Napolitano F, Gualdieri L, Santagati G, Angelillo IF.

Vaccine. 2018 Nov 26;36(49):7536-7541. doi: 10.1016/j.vaccine.2018.10.050. Epub 2018 Oct 24.

PMID:
30420043
20.

Prevalence and distribution of human papillomavirus genotypes among women with high-grade squamous intraepithelial lesion and invasive cervical cancer in Ganzhou, China.

Liao L, Cheng H, Zeng F, Zhou W, Ding Y.

J Clin Lab Anal. 2019 Mar;33(3):e22708. doi: 10.1002/jcla.22708. Epub 2018 Nov 2.

PMID:
30390349

Supplemental Content

Loading ...
Support Center